http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015073330-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea3042c650fa788ee6705b6943e5d3d4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-327 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-325 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-0546 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-306 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-303 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M31-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M31-00 |
| filingDate | 2014-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d60ca2de140168c41ca6b7bb8c3e5c98 |
| publicationDate | 2015-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2015073330-A1 |
| titleOfInvention | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
| abstract | This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11426577-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018039602-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021188825-A1 |
| priorityDate | 2012-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1320.